BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 19227950)

  • 1. [Treatment of Waldenström macroglobulinaemia--the experience of one centre].
    Adam Z; Pour L; Krejcí M; Korístek Z; Navrátil M; Krivanová A; Zahradová L; Hájek R
    Vnitr Lek; 2009 Jan; 55(1):9-17. PubMed ID: 19227950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
    Leleu X; Soumerai J; Roccaro A; Hatjiharissi E; Hunter ZR; Manning R; Ciccarelli BT; Sacco A; Ioakimidis L; Adamia S; Moreau AS; Patterson CJ; Ghobrial IM; Treon SP
    J Clin Oncol; 2009 Jan; 27(2):250-5. PubMed ID: 19064987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.
    Annibali O; Petrucci MT; Martini V; Tirindelli MC; Levi A; Fossati C; Del Bianco P; Mandelli F; Foa R; Avvisati G
    Cancer; 2005 Feb; 103(3):582-7. PubMed ID: 15611977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia.
    Munshi NC; Barlogie B
    Semin Oncol; 2003 Apr; 30(2):282-5. PubMed ID: 12720153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
    Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Zervas K; Tsatalas C; Kokkinis G; Repoussis P; Symeonidis A; Delimpasi S; Katodritou E; Vervessou E; Michali E; Pouli A; Gika D; Vassou A; Terpos E; Anagnostopoulos N; Economopoulos T; Pangalis G
    J Clin Oncol; 2007 Aug; 25(22):3344-9. PubMed ID: 17577016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
    Radocha J; Maisnar V
    Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
    Ise M; Sakai C; Kumagai K
    Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
    Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
    Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.
    Treon SP; Agus DB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother (1991); 2001 May; 24(3):272-279. PubMed ID: 11395644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
    Shin SJ; Chun SH; Kim KO; Kim MK; Lee KH; Hyun MS; Cho HS
    Jpn J Clin Oncol; 2005 Oct; 35(10):622-5. PubMed ID: 16172172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Waldenstrom's macroglobulinemia: a retrospective analysis of 40 patients from 1972 to 2001.
    Ngan S; Rohatiner AZ; Matthews J; Williams A; Amess JA; Norton A; Lister TA
    Semin Oncol; 2003 Apr; 30(2):236-8. PubMed ID: 12720143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
    Ghobrial IM; Fonseca R; Greipp PR; Blood E; Rue M; Vesole DH; Gertz MA;
    Cancer; 2004 Dec; 101(11):2593-8. PubMed ID: 15493038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplantation in Waldenstrom's macroglobulinemia--the French experience.
    Tournilhac O; Leblond V; Tabrizi R; Gressin R; Senecal D; Milpied N; Cazin B; Divine M; Dreyfus B; Cahn JY; Pignon B; Desablens B; Perrier JF; Bay JO; Travade P
    Semin Oncol; 2003 Apr; 30(2):291-6. PubMed ID: 12720155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The treatment of Waldenström macroglobulinemia and the therapy of diseases caused by monoclonal IgM gammaglobulin].
    Adam Z; Scudla V; Krejcí M; Korístek Z
    Vnitr Lek; 2008 Jan; 54(1):68-83. PubMed ID: 18390120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution.
    Breccia M; Mandelli F; Petti MC; D'Andrea M; Pescarmona E; Pileri SA; Carmosino I; Russo E; De Fabritiis P; Alimena G
    Leuk Res; 2004 Nov; 28(11):1165-9. PubMed ID: 15380340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases.
    Huang YW; Saidi P; Philipp C
    Haemophilia; 2004 Nov; 10(6):713-21. PubMed ID: 15569166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.